Naoki Iwamoto

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3447396/publications.pdf

Version: 2024-02-01

516710 677142 41 573 16 22 citations h-index g-index papers 43 43 43 915 all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	Selection of treatment regimens based on shared decision-making in patients with rheumatoid arthritis on remission in the FREE-J study. Rheumatology, 2022, 61, 4273-4285.	1.9	3
2	Comparison of complications during 1-year follow-up between remitting seronegative symmetrical synovitis with pitting edema syndrome and elderly-onset rheumatoid arthritis. Immunological Medicine, 2022, , 1-7.	2.6	2
3	Serum checkpoint molecules in patients with IgG4-related disease (IgG4-RD). Arthritis Research and Therapy, 2021, 23, 148.	3.5	6
4	Real-world comparative effectiveness and safety of tofacitinib and baricitinib in patients with rheumatoid arthritis. Arthritis Research and Therapy, 2021, 23, 197.	3.5	26
5	Methotrexate Alters the Expression of microRNA in Fibroblast-like Synovial Cells in Rheumatoid Arthritis. International Journal of Molecular Sciences, 2021, 22, 11561.	4.1	9
6	Comparison of the quantitative measurement of 18F-FDG PET/CT and histopathological findings in IgG4-related disease. Clinical and Experimental Rheumatology, 2021, 39, 1338-1344.	0.8	0
7	Anti-EJ Antibody-positive Anti-synthetase Syndrome Associated with Retroperitoneal Sarcoma. Internal Medicine, 2020, 59, 2071-2076.	0.7	4
8	Differences in musculoskeletal ultrasound findings between RS3PE syndrome and elderly-onset rheumatoid arthritis. Clinical Rheumatology, 2020, 39, 1981-1988.	2.2	9
9	Comparative study of the inhibitory effect on bone erosion progression with denosumab treatment and conventional treatment in rheumatoid arthritis patients: study protocol for an open-label randomized controlled trial by HR-pQCT. Trials, 2019, 20, 494.	1.6	10
10	AB0172â€EXPRESSION OF SLAMF6 AND ITS FUNCTIONAL SIGNIFICANCE IN PODOCYTES OF LUPUS NEPHRITIS 2019, , .	S., 	0
11	Recent findings regarding the effects of microRNAs on fibroblast-like synovial cells in rheumatoid arthritis. Immunological Medicine, 2019, 42, 156-161.	2.6	12
12	Denosumab is effective toward glucocorticoid-induced osteoporosis patients complicated with rheumatic diseases regardless of prior anti-osteoporotic drugs. Journal of Bone and Mineral Metabolism, 2019, 37, 554-562.	2.7	14
13	Antineutrophilic cytoplasmic antibodyâ€associated vasculitis with and without renal involvement: C3 contributes to prognosis, but renal involvement does not. International Journal of Rheumatic Diseases, 2019, 22, 789-796.	1.9	9
14	Osteogenic differentiation of fibroblast-like synovial cells in rheumatoid arthritis is induced by microRNA-218 through a ROBO/Slit pathway. Arthritis Research and Therapy, 2018, 20, 189.	3.5	34
15	Rituximab-induced Acute Thrombocytopenia in Granulomatosis with Polyangiitis. Internal Medicine, 2018, 57, 2247-2250.	0.7	7
15 16		0.7	6
	2018, 57, 2247-2250. Synovitis of sternoclavicular and peripheral joints can be detected by ultrasound in patients with		

#	Article	IF	CITATIONS
19	Efficacy and safety at 24 weeks of daily clinical use of tofacitinib in patients with rheumatoid arthritis. PLoS ONE, 2017, 12, e0177057.	2.5	23
20	Magnetic Resonance Imaging Bone Edema at Enrollment Predicts Rapid Radiographic Progression in Patients with Early RA: Results from the Nagasaki University Early Arthritis Cohort. Journal of Rheumatology, 2016, 43, 1278-1284.	2.0	14
21	Fewer subsequent relapses and lower levels of IL-17 in Takayasu arteritis developed after the age of 40Âyears. Arthritis Research and Therapy, 2016, 18, 293.	3.5	10
22	Antineutrophilic cytoplasmic antibody-associated vasculitis with hypocomplementemia has a higher incidence of serious organ damage and a poor prognosis. Medicine (United States), 2016, 95, e4871.	1.0	34
23	Bioanalysis of bevacizumab and infliximab by high-temperature reversed-phase liquid chromatography with fluorescence detection after immunoaffinity magnetic purification. Analytica Chimica Acta, 2016, 916, 112-119.	5.4	28
24	Evaluation of switching from intravenous to subcutaneous formulation of tocilizumab in patients with rheumatoid arthritis. Modern Rheumatology, 2016, 26, 662-666.	1.8	19
25	Upregulation of Thrombospondin 1 Expression in Synovial Tissues and Plasma of Rheumatoid Arthritis: Role of Transforming Growth Factor- \hat{l}^2 1 toward Fibroblast-like Synovial Cells. Journal of Rheumatology, 2015, 42, 943-947.	2.0	21
26	Synovial inflammation assessed by ultrasonography correlates with MRI-proven osteitis in patients with rheumatoid arthritis. Rheumatology, 2014, 53, 1452-1456.	1.9	21
27	An elderly patient with chronic active Epstein–Barr virus infection with mixed cryoglobulinemia and review of the literature. Modern Rheumatology, 2013, 23, 1022-1028.	1.8	4
28	Magnetic resonance imaging (MRI) detection of synovitis and bone lesions of the wrists and finger joints in early-stage rheumatoid arthritis: comparison of the accuracy of plain MRI-based findings and gadolinium-diethylenetriamine pentaacetic acid-enhanced MRI-based findings. Modern Rheumatology, 2012, 22, 654-658.	1.8	28
29	Disease activity score 28 may overestimate the remission induction of rheumatoid arthritis patients treated with tocilizumab: comparison with the remission by the clinical disease activity index. Modern Rheumatology, 2011, 21, 365-369.	1.8	27
30	Reduction in serum levels of substance P in patients with rheumatoid arthritis by etanercept, a tumor necrosis factor inhibitor. Modern Rheumatology, 2011, 21, 244-250.	1.8	17
31	In rheumatoid arthritis patients treated with tocilizumab, the rate of clinical disease activity index (CDAI) remission at 24 weeks is superior in those with higher titers of IgM-rheumatoid factor at baseline. Modern Rheumatology, 2011, 21, 370-374.	1.8	16
32	Contribution of an adenine to guanine single nucleotide polymorphism of the matrix metalloproteinase-13 (MMP-13) â^777 promoter region to the production of anticyclic citrullinated peptide antibodies in patients with HLA-DRB1*shared epitope-negative rheumatoid arthritis. Modern Rheumatology, 2011, 21, 240-243.	1.8	1
33	Contribution of an adenine to guanine single nucleotide polymorphism of the matrix metalloproteinase-13 (MMP-13) â^'77 promoter region to the production of anticyclic citrullinated peptide antibodies in patients with HLA-DRB1*shared epitope-negative rheumatoid arthritis. Modern Rheumatology, 2011, 21, 240-243.	1.8	3
34	Cutaneous vasculitis induced by TNF inhibitors: a report of three cases. Modern Rheumatology, 2010, 20, 86-89.	1.8	37
35	Switching to the anti-interleukin-6 receptor antibody tocilizumab in rheumatoid arthritis patients refractory to antitumor necrosis factor biologics. Modern Rheumatology, 2010, 20, 40-45.	1.8	11
36	Regulation of disease susceptibility and mononuclear cell infiltration into the labial salivary glands of Sjogren's syndrome by monocyte chemotactic protein-1. Rheumatology, 2010, 49, 1472-1478.	1.9	12

#	Article	IF	CITATIONS
37	Successful treatment of chronic lupus myocarditis with prednisolone and mizoribine. Modern Rheumatology, 2010, 20, 606-610.	1.8	4
38	Prediction of DAS28-CRP remission in patients with rheumatoid arthritis treated with tacrolimus at 6 months by baseline variables. Modern Rheumatology, 2009, 19, 652-656.	1.8	6
39	Prediction of DAS28-ESR remission at 6 months by baseline variables in patients with rheumatoid arthritis treated with etanercept in Japanese population. Modern Rheumatology, 2009, 19, 488-492.	1.8	20
40	Determination of the Subset of Sjögren's Syndrome with Articular Manifestations by Anticyclic Citrullinated Peptide Antibodies. Journal of Rheumatology, 2009, 36, 113-115.	2.0	28
41	Prediction of DAS28-ESR remission at 6Âmonths by baseline variables in patients with rheumatoid arthritis treated with etanercept in Japanese population. Modern Rheumatology, 2009, 19, 488-492.	1.8	19